Athersys, Inc. (NASDAQ:ATHX) headquartered in Cleveland, will host a conference call for the investment community to discuss the 3Q20 earnings result on 9th November 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.athersys.com
Earnings Expectation
Athersys, Inc. is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.09 per share from $ 0.17 million in revenue. For the full year, analysts predict revenues of $ 0.41 million, while looking forward to loss of $ 0.36 per share.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companys lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.
